Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 2/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.38 |
| ▸ | MARS1 | P56192 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494874 | 0.90 | L3MBTL1 (0.35) | SHMT1SHMT2MARS1NPC1DPP4 | |
| SCHEMBL6498656 | 0.71 | NPC1 (0.44) | MARS1NPC1 | |
| SCHEMBL6070738 | 0.68 | CRHR1 (0.45) | NPC1DPP4 | |
| SCHEMBL1943591 | 0.65 | EGLN2 (0.49) | MARS1NPC1HTT | |
| SCHEMBL14014232 | 0.63 | KDM4E (0.53) | MARS1NPC1 | |
| SCHEMBL6500995 | 0.61 | CRHR1 (0.41) | — | |
| SCHEMBL7423913 | 0.61 | SHMT1 (0.58) | SHMT1SHMT2NPC1SMN1; SMN2CYP2C9 | |
| SCHEMBL14014193 | 0.60 | KDM4E (0.60) | MARS1SMN1; SMN2 | |
| SCHEMBL14014214 | 0.60 | KDM4E (0.59) | MARS1 | |
| SCHEMBL14014255 | 0.60 | KDM4E (0.69) | MARS1HTTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | claimed |
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | WILDE RICHARD G (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | CRHR1, CRHR2, CRH | SHMT1 3970/4885SHMT2 4056/4885MARS1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.